白细胞介素22结合蛋白在炎症相关性疾病中的研究进展

doi:10.11958/20220999

天津医药 ›› 2023, Vol. 51 ›› Issue (1): 109-112.doi: 10.11958/20220999

• 综述 • 上一篇

白细胞介素22结合蛋白在炎症相关性疾病中的研究进展

时静祥(), 曹际森, 张金卷, 王毅军()

天津市第三中心医院肝胆外科，天津市重症疾病体外生命支持重点实验室，天津市人工细胞工程技术研究中心，天津市肝胆疾病研究所（邮编300170

收稿日期:2022-07-07 修回日期:2022-09-16 出版日期:2023-01-15 发布日期:2023-01-17
通讯作者: 王毅军 E-mail:18002180065@163.com;wangyijun_carl@163.com
作者简介:时静祥（1982），男，副主任医师，主要从事肝癌免疫相关方面研究。E-mail：18002180065@163.com
基金资助:
天津市医学重点学科（专科）建设项目(TJYXZDXK-034A)

Research progress of interleukin 22 binding protein in inflammation related diseases

SHI Jingxiang(), CAO Jisen, ZHANG Jinjuan, WANG Yijun()

Department of Hepatobiliary Surgery, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Third Central Hospital of Tianjin, Tianjin 300170, China

Received:2022-07-07 Revised:2022-09-16 Published:2023-01-15 Online:2023-01-17
Contact: WANG Yijun E-mail:18002180065@163.com;wangyijun_carl@163.com

时静祥, 曹际森, 张金卷, 王毅军. 白细胞介素22结合蛋白在炎症相关性疾病中的研究进展[J]. 天津医药, 2023, 51(1): 109-112.

SHI Jingxiang, CAO Jisen, ZHANG Jinjuan, WANG Yijun. Research progress of interleukin 22 binding protein in inflammation related diseases[J]. Tianjin Medical Journal, 2023, 51(1): 109-112.

摘要/Abstract

摘要：

白细胞介素22结合蛋白（IL-22BP）是一种可溶性受体同系物，与白细胞介素受体（IL-22R）具有高度同源性，且其与白细胞介素（IL）-22结合的亲和力远高于IL-22R。IL-22BP可通过与IL-22结合抑制其表达来发挥维持机体免疫稳态的作用。该文对IL-22BP的产生、调节、分型以及在炎症相关性疾病中的研究进展加以综述，并探讨其作为治疗靶标的可行性。

关键词: 白细胞介素22, 细胞因子, 免疫, 白细胞介素22结合蛋白, 炎症相关性疾病

Abstract:

Interleukin 22 binding protein (IL-22BP) is a soluble receptor homolog that binds to interleukin 22 (IL-22) with greater affinity than the membrane spanning receptor. IL-22BP can play a role in maintaining immune homeostasis by inhibiting its expression and combining with IL-22. This review will focus on the production, regulation, typing of IL-22BP and its research progress in inflammatory related diseases, and explore the feasibility of it as a therapeutic target.

Key words: interleukin 22, cytokine, immunity, interleukin 22 binding protein, inflammation related diseases

中图分类号:

R392.12

参考文献 40

[1]	ZENEWICZ L A. IL-22 Binding Protein (IL-22BP) in the regulation of IL-22 biology[J]. Front Immunol, 2021, 12:766586. doi:10.3389/fimmu.2021.766586.
[2]	LÜCKE J, SABIHI M, ZHANG T, et al. The good and the bad about separation anxiety:Roles of IL-22 and IL-22BP in liver pathologies[J]. Semin Immunopathol, 2021, 43(4):591-607. doi:10.1007/s00281-021-00854-z.
[3]	LOPEZ D V, KONGSBAK-WISMANN M. Role of IL-22 in homeostasis and diseases of the skin[J]. APMIS, 2022, 130(6):314-322. doi:10.1111/apm.13221.
[4]	NGUYEN H M, TORRES J A, AGRAWAL S, et al. Nicotine impairs the response of lung epithelial cells to IL-22[J]. Mediators Inflamm, 2020, 2020:6705428. doi:10.1155/2020/6705428.
[5]	KEIR M, YI Y, LU T, et al. The role of IL-22 in intestinal health and disease[J]. J Exp Med, 2020, 217(3):e20192195. doi:10.1084/jem.20192195.
[6]	MÜHL H, BACHMANN M. IL-18/IL-18BP and IL-22/IL-22BP:Two interrelated couples with therapeutic potential[J]. Cell Signal, 2019, 63:109388. doi:10.1016/j.cellsig.2019.109388.
[7]	LUO J W, HU Y, LIU J, et al. Interleukin-22:A potential therapeutic target in atherosclerosis[J]. Mol Med, 2021, 27(1):88. doi:10.1186/s10020-021-00353-9.
[8]	MA Q, LUAN J, BAI Y, et al. Interleukin-22 in renal protection and its pathological role in kidney diseases[J]. Front Immunol, 2022, 13:851818. doi:10.3389/fimmu.2022.851818.
[9]	DE MOURA P R, WATANABE L, BLEICHER L, et al. Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22[J]. FEBS Lett, 2009, 583(7):1072-1077. doi:10.1016/j.febslet.2009.03.006.
[10]	OUYANG W, O'GARRA A. IL-10 Family Cytokines IL-10 and IL-22:from basic science to clinical translation[J]. Immunity, 2019, 50(4):871-891. doi:10.1016/j.immuni.2019.03.020.
[11]	JONES B C, LOGSDON N J, WALTER M R. Structure of IL-22 bound to its high-affinity IL-22R1 chain[J]. Structure, 2008, 16(9):1333-1344. doi:10.1016/j.str.2008.06.005.
[12]	GUENDEL F, KOFOED-BRANZK M, GRONKE K, et al. Group 3 innate lymphoid cells program a distinct subset of IL-22BP-producing dendritic cells demarcating solitary intestinal lymphoid tissues[J]. Immunity, 2020, 53(5):1015-1032.e8. doi:10.1016/j.immuni.2020.10.012.
[13]	NINNEMANN J, WINSAUER C, BONDAREVA M, et al. TNF hampers intestinal tissue repair in colitis by restricting IL-22 bioavailability[J]. Mucosal Immunol, 2022, 15(4):698-716. doi:10.1038/s41385-022-00506-x.
[14]	PELCZAR P, WITKOWSKI M, PEREZ L G, et al. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease[J]. Science, 2016, 354(6310):358-362. doi:10.1126/science.aah5903.
[15]	MARTIN J C, BERIOU G, HESLAN M, et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid[J]. Mucosal Immunol, 2014, 7(1):101-113. doi:10.1038/mi.2013.28.
[16]	WANG B, HAN D, LI F, et al. Elevated IL-22 in psoriasis plays an anti-apoptotic role in keratinocytes through mediating Bcl-xL/Bax[J]. Apoptosis, 2020, 25(9/10):663-673. doi:10.1007/s10495-020-01623-3.
[17]	GÓMEZ-FERNÁNDEZ P, LOPEZ DE LAPUENTE PORTILLA A, ASTOBIZA I, et al. The rare IL22RA2 signal peptide coding variant rs28385692 decreases secretion of IL-22BP isoform-1,-2 and -3 and is associated with risk for multiple sclerosis[J]. Cells, 2020, 9(1):175. doi:10.3390/cells9010175.
[18]	TREVEJO-NUNEZ G, ELSEGEINY W, AGGOR F E Y, et al. Interleukin-22 (IL-22) binding protein constrains IL-22 activity,host defense,and oxidative phosphorylation genes during pneumococcal pneumonia[J]. Infect Immun, 2019, 87(11):e00550-19. doi:10.1128/IAI.00550-19.
[19]	KARTASHEVA-EBERTZ D M, POL S, LAGAYE S. Retinoic acid:A new old friend of IL-17A in the immune pathogeny of liver fibrosis[J]. Front Immunol, 2021, 12:691073. doi:10.3389/fimmu.2021.691073.
[20]	TAMEHIRO N, NISHIDA K, SUGITA Y, et al. Ras homolog gene family H(RhoH)deficiency induces psoriasis-like chronic dermatitis by promoting T_H17 cell polarization[J]. J Allergy Clin Immunol, 2019, 143(5):1878-1891. doi:10.1016/j.jaci.2018.09.032.
[21]	VOGLIS S, MOOS S, KLOOS L, et al. Regulation of IL-22BP in psoriasis[J]. Sci Rep, 2018, 8(1):5085. doi:10.1038/s41598-018-23510-3.
[22]	SABIHI M, BÖTTCHER M, PELCZAR P, et al. Microbiota-dependent effects of IL-22[J]. Cells, 2020, 9(10):2205. doi:10.3390/cells9102205.
[23]	HEBERT K D, MCLAUGHLIN N, GALEAS-PENA M, et al. Targeting the IL-22/IL-22BP axis enhances tight junctions and reduces inflammation during influenza infection[J]. Mucosal Immunol, 2020, 13(1):64-74. doi:10.1038/s41385-019-0206-9.
[24]	HUBER S, GAGLIANI N, ZENEWICZ L A, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine[J]. Nature, 2012, 491(7423):259-263. doi:10.1038/nature11535.
[25]	ZHUANG L, MA W, YAN J, et al. Evaluation of the effects of IL-22 on the proliferation and differentiation of keratinocytes in vitro[J]. Mol Med Rep, 2020, 22(4):2715-2722. doi:10.3892/mmr.2020.11348.
[26]	EKMAN A K, BIVIK EDING C, RUNDQUIST I, et al. IL-17 and IL-22 promote keratinocyte stemness in the germinative compartment in psoriasis[J]. J Invest Dermatol, 2019, 139(7):1564-1573.e8. doi:10.1016/j.jid.2019.01.014.
[27]	MARTIN J C, WOLK K, BERIOU G, et al. Limited presence of IL-22 binding protein,a natural IL-22 inhibitor,strengthens psoriatic skin inflammation[J]. J Immunol, 2017, 198(9):3671-3678. doi:10.4049/jimmunol.1700021.
[28]	FUKAYA T, FUKUI T, UTO T, et al. Pivotal role of IL-22 binding protein in the epithelial autoregulation of interleukin-22 signaling in the control of skin inflammation[J]. Front Immunol, 2018, 9:1418. doi:10.3389/fimmu.2018.01418.
[29]	BRUNNER P M, PAVEL A B, KHATTRI S, et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab[J]. J Allergy Clin Immunol, 2019, 143(1):142-154. doi:10.1016/j.jaci.2018.07.028.
[30]	JINNOHARA T, KANAYA T, HASE K, et al. IL-22BP dictates characteristics of Peyer's patch follicle-associated epithelium for antigen uptake[J]. J Exp Med, 2017, 214(6):1607-1618. doi:10.1084/jem.20160770.
[31]	WEI H X, WANG B, LI B. IL-10 and IL-22 in mucosal immunity:Driving protection and pathology[J]. Front Immunol, 2020, 11:1315. doi:10.3389/fimmu.2020.01315.
[32]	PEREZ L G, KEMPSKI J, MCGEE H M, et al. TGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer[J]. Nat Commun, 2020, 11(1):2608. doi:10.1038/s41467-020-16363-w.
[33]	KEMPSKI J, GIANNOU A D, RIECKEN K, et al. IL22BP mediates the antitumor effects of lymphotoxin against colorectal tumors in mice and humans[J]. Gastroenterology, 2020, 159(4):1417-1430.e3. doi:10.1053/j.gastro.2020.06.033.
[34]	STOY S, LAURSEN T L, GLAVIND E, et al. Low interleukin-22 binding protein is associated with high mortality in alcoholic hepatitis and modulates interleukin-22 receptor expression[J]. Clin Transl Gastroenterol, 2020, 11(8):e00197. doi:10.14309/ctg.0000000000000197.
[35]	KLEINSCHMIDT D, GIANNOU A D, MCGEE H M, et al. A protective function of IL-22BP in ischemia reperfusion and acetaminophen-induced liver injury[J]. J Immunol, 2017, 199(12):4078-4090. doi:10.4049/jimmunol.1700587.
[36]	SCHWARZKOPF K, RÜSCHENBAUM S, BARAT S, et al. IL-22 and IL-22-binding protein are associated with development of and mortality from acute-on-chronic liver failure[J]. Hepatol Commun, 2019, 3(3):392-405. doi:10.1002/hep4.1303.
[37]	DE BRITO R J V C, DO CARMO R F, SILVA B M S, et al. Liver expression of IL-22,IL-22R1 and IL-22BP in patients with chronic hepatitis C with different fibrosis stages[J]. Cytokine, 2022, 150:155784. doi:10.1016/j.cyto.2021.155784.
[38]	ABOOD R N, MCHUGH K J, RICH H E, et al. IL-22-binding protein exacerbates influenza,bacterial super-infection[J]. Mucosal Immunol, 2019, 12(5):1231-1243. doi:10.1038/s41385-019-0188-7.
[39]	LINDAHL H, GUERREIRO-CACAIS A O, BEDRI S K, et al. IL-22 binding protein promotes the disease process in multiple sclerosis[J]. J Immunol, 2019, 203(4):888-898. doi:10.4049/jimmunol.1900400.
[40]	SERTORIO M, HOU X, CARMO R F, et al. IL-22 and IL-22 binding protein (IL-22BP)regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections[J]. Hepatology, 2015, 61(4):1321-1331. doi:10.1002/hep.27629.

白细胞介素22结合蛋白在炎症相关性疾病中的研究进展

Research progress of interleukin 22 binding protein in inflammation related diseases

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	白梦刻, 杨晓青, 李航, 王龙, 马继伟. 过敏性紫癜肾炎伴新月体形成患儿的实验室指标和病理特征分析[J]. 天津医药, 2024, 52(8): 820-824.
[2]	张国华, 张令令, 高兰, 罗俊丽, 申雅文, 刘磊, 王玉华. 结缔组织病相关间质性肺病合并肺癌16例临床分析[J]. 天津医药, 2024, 52(7): 687-690.
[3]	刘青青, 李宜蔷, 石玉士, 陆海颂, 程纬民. TGF-β信号通路在骨髓增生异常综合征中作用机制的研究进展[J]. 天津医药, 2024, 52(7): 781-784.
[4]	霍晶辰, 王悦, 李华, 邱嵘, 苏景伟, 王卓凡, 杨洁. 系统免疫炎症指数对根治性放疗Ⅲ期肺鳞癌患者长期生存的预测价值[J]. 天津医药, 2024, 52(6): 634-638.
[5]	吴倩, 王意, 陈念, 周凯, 田昕, 徐晖, 苟小霞. 诱导化疗对鼻咽癌患者免疫功能及炎症指标的影响[J]. 天津医药, 2024, 52(4): 397-402.
[6]	单子鸿, 胡晓青, 李峰, 黄永坤. 5-羟色胺在胃肠道疾病中的作用及其机制研究进展[J]. 天津医药, 2024, 52(4): 438-442.
[7]	张文超, 杨雪辉, 尹涛, 王睿健, 张盟盟. 自发性急性脑出血患者血浆sCD163/sTWEAK比值与预后的关系[J]. 天津医药, 2024, 52(3): 297-301.
[8]	张玉龙, 张静, 李树军, 马龙, 祖建兵, 孙丹丹. 再生障碍性贫血患者血清sFasL、SDF-1与免疫抑制疗效的相关性[J]. 天津医药, 2024, 52(12): 1270-1273.
[9]	姚茜, 王晶, 程娜. 神曲消食口服液治疗小儿轮状病毒感染性腹泻的疗效观察[J]. 天津医药, 2024, 52(12): 1296-1300.
[10]	屠昌明, 田园, 汪鹏程, 任鹏, 赵寅生. SII、RAR与AECOPD患者病情严重程度及并发呼吸衰竭的关系[J]. 天津医药, 2024, 52(12): 1317-1321.
[11]	张婕, 苗耐英, 李欢, 刘新建. 奥曲肽对新生儿坏死性小肠结肠炎患儿粪便性状及体液免疫的影响[J]. 天津医药, 2024, 52(12): 1331-1334.
[12]	宫秀娟, 赵慧霞, 张小庆, 张连霞. 重症社区获得性肺炎患者PIV、IL-6、HBP、PAB水平对疗效的评估价值[J]. 天津医药, 2024, 52(11): 1216-1220.
[13]	杨文珊, 盛玉, 陈秀利, 陈吉. 小儿急性胰腺炎序贯化营养支持与肠外营养支持的疗效比较[J]. 天津医药, 2024, 52(10): 1061-1064.
[14]	秦宗碧, 徐爱琴, 蔡翔, 邱百怡, 王首帆, 李伶华, 朱立宏. 黄连素调节PI3K/AKT/NF-κB信号通路对慢性湿疹大鼠皮肤损伤的影响[J]. 天津医药, 2023, 51(8): 834-840.
[15]	张晓宇, 任悦, 刘伟, 苗彦玲, 张辉, 靳丽君, 张恒乐, 康晓宁, 白杰, 王遵义. 新辅助化疗联合PD-1抑制剂治疗三阴性乳腺癌的临床疗效[J]. 天津医药, 2023, 51(8): 847-850.